Mesa Laboratories (NASDAQ:MLAB) Announces Quarterly Earnings Results

Mesa Laboratories (NASDAQ:MLAB) posted its quarterly earnings data on Monday. The medical instruments supplier reported $2.68 EPS for the quarter, reports. The company had revenue of $60.14 million for the quarter. Mesa Laboratories had a return on equity of 22.87% and a net margin of 1.92%.

Here are the key takeaways from Mesa Laboratories’ conference call:

• Revenue returned to organic growth: First-quarter revenue rose 1% to $60.1 million, while adjusted operating income increased 16.5% to $15.0 million, with adjusted margin expanding to 25.6%.
• Core franchises showed growth: Biopharmaceutical Development grew 5% organically, Calibration Solutions grew 7.6%, and trailing-12-month Sterilization and Disinfection Control revenue increased about 5%, despite quarterly delivery delays.
• SDC execution remains a key risk: Sterilization and Disinfection Control revenue declined 3.6% year over year as missed delivery dates increased past-due backlog by approximately $1 million; management characterized this as a reliability issue rather than weak demand but did not provide a recovery timetable.
• Management is prioritizing internal improvements over acquisitions: Mesa repaid $8.7 million of debt, reduced net leverage to 1.85x, and is targeting 1.5x–1.75x by fiscal year-end while reallocating resources toward higher-return businesses.
• Growth initiatives are still developing: A new BPD general manager is rebuilding the commercial organization, and Mesa accelerated development of a next-generation Gyrolab platform targeted for fiscal 2028; full-year fiscal 2027 guidance is deferred until November.

Mesa Laboratories Price Performance

MLAB traded up $0.38 during trading on Wednesday, reaching $111.61. 133,550 shares of the company were exchanged, compared to its average volume of 147,209. Mesa Laboratories has a 12-month low of $58.83 and a 12-month high of $113.99. The company has a market cap of $625.02 million, a price-to-earnings ratio of 132.87 and a beta of 0.92. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78. The company’s 50-day moving average is $100.34 and its two-hundred day moving average is $95.50.

Mesa Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be given a dividend of $0.16 per share. The ex-dividend date is Monday, August 31st. This represents a $0.64 annualized dividend and a dividend yield of 0.6%. Mesa Laboratories’s dividend payout ratio is currently 53.33%.

Insider Buying and Selling

In other Mesa Laboratories news, CAO Lyndsey Elizabeth Crennen sold 442 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $39,559.00. Following the transaction, the chief accounting officer directly owned 2,020 shares in the company, valued at $180,790. This trade represents a 17.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO John Sakys sold 2,827 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $253,016.50. Following the transaction, the chief financial officer directly owned 19,785 shares in the company, valued at $1,770,757.50. This trade represents a 12.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 8,277 shares of company stock worth $770,122 over the last ninety days. 2.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mesa Laboratories

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. lifted its position in Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Mesa Laboratories in the fourth quarter worth approximately $27,000. Kestra Advisory Services LLC bought a new position in shares of Mesa Laboratories in the fourth quarter worth approximately $55,000. BNP Paribas Financial Markets increased its stake in shares of Mesa Laboratories by 30.9% in the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock worth $69,000 after buying an additional 243 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after buying an additional 684 shares during the last quarter. 90.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and an average price target of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.